Health Condition 1: E230- Hypopituitarism
Conditions
Interventions
Intervention1: Somatrogon 24 mg/1.2 mL solution for injection in pre-filled pen
: Somatrogon 24 mg/1.2 mL solution for injection in pre-filled pen (Genryzon) administered once weekly by subcutaneous i
Sponsors
Pfizer Products India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Prescription of Somatrogon for p GHD in participants aged 3 years or more. 2. Evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed and agree to all pertinent aspects of the study. Assent will also be sought from children of applicable age in line with national guidance. In all cases, the treating physician responsible for enrolling the participant into the study will assess the appropriateness of gaining assent from a participant (or a legally acceptable representative) at their discretion during routine clinical care.
Exclusion criteria
Exclusion criteria: 1. Participation in any interventional clinical trials at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate incidence rates (IRs) of safety events of interest among participants on Somatrogon.Timepoint: Data will be collected at baseline, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate treatment adherence and compliance of SomatrogonTimepoint: Data will be collected at baseline, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months | — |
Countries
India
Contacts
Public ContactDr Mukundraj Keny
Pfizer Products India Private Limited
Outcome results
None listed